Latest News & Updates from the HEALEY ALS Platform Trial
Jul 15, 2024 · The ALS Association announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).
HEALEY ALS Platform Trial - Massachusetts General Hospital
This is the first ALS platform trial, accelerating the path to new ALS therapies by testing multiple treatments at once, reducing the cost of research by 30%, decreasing the trial time by 50% and increasing patient participation by 67%.
HEALEY ALS trial to allow longer follow-up, blood cell collection
Dec 20, 2024 · The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a longer follow-up time and collection of blood cells for use in future research.
Sean M. Healey & AMG Center Announces Updates to HEALEY ALS Platform ...
Today, the Healey & AMG Center announced updates to the Master Protocol for the trial. The platform trial’s perpetual and adaptive design allows for the integration of new information based on experience, the analysis of data, and feedback from participants.
CNM-Au8 Shows Significant Long-Term Survival Improvement in HEALEY ALS …
Sep 25, 2023 · In an integrated meta-analysis of the HEALEY ALS platform trial and RESCUE-ALS trial, 30mg of CNM-Au8 resulted in 59% decreased risk of mortality among participants with ALS compared with PRO-ACT matched placebo over long-term follow-up.
Results of HEALEY ALS trials show progress in the field
Oct 19, 2023 · The multicentre, double-blind, placebo-controlled, perpetual and adaptive platform trial tests multiple investigational products in parallel to discover safe and effective treatments for people living with ALS.
New Results From HEALEY ALS Platform Trial Show Promise for …
Oct 17, 2023 · Recently, based on results of the HEALEY ALS Platform Trial, two experimental medications plan to move to phase 3 clinical trials. This means the drugs will now be tested on a larger...
The HEALEY Platform Trial: Quick Failures and New Hope for ALS
Sep 16, 2024 · Launched in 2020 to more quickly bring to market an effective medicine for amyotrophic lateral sclerosis, the HEALEY Platform Trial has generated disappointing results for many but also continuing programs from Clene and Prilenia.
FDA Gives OK to HEALEY ALS Platform Trial Testing First Three...
Jan 27, 2020 · The U.S. Food and Drug Administration (FDA) has authorized the evaluation of the first three candidate therapies for amyotrophic lateral sclerosis (ALS) in the HEALEY ALS Platform Trial. This trial model, designed to accelerate the development of ALS therapies by assessing multiple treatment candidates simultaneously, is the first of its kind ...
AAN 2023: ALS treatments ID’d in HEALEY head toward Phase 3 …
Apr 27, 2023 · The HEALEY platform trial (NCT04297683), led by the Sean M. Healey & AMG Center for ALS at MGH, intends to test multiple potential ALS therapies at once, an approach that may help reduce the cost and time associated with drug development.
- Some results have been removed